Cerebral venous sinus thrombosis after vaccination: the UK experience

Abstract

An important but rare complication of COVID-19 vaccination is vaccine-induced immune thrombotic thrombocytopenia (VITT) associated with the adenovirus vector vaccines, Ad26.COV2.S (Johnson & Johnson) and ChAdOx1 (Oxford–AstraZeneca).1–5 VITT occurs more commonly in women younger than 50 years who present within 5–24 days of vaccination with thrombosis in unusual sites—the majority with cerebral venous sinus thrombosis.1,6 Thrombocytopenia, elevated D-dimer, decreased fibrinogen, and positive antibodies against platelet factor 4 (PF4) are commonly observed.